228 related articles for article (PubMed ID: 17724361)
1. Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery.
Johnson SJ; Ross MB; Moores KG
Am J Health Syst Pharm; 2007 Sep; 64(17):1808-12. PubMed ID: 17724361
[TBL] [Abstract][Full Text] [Related]
2. Unlabeled uses of factor VIIa (recombinant) in pediatric patients.
Hong I; Stachnik J
Am J Health Syst Pharm; 2010 Nov; 67(22):1909-19. PubMed ID: 21048207
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting.
Logan AC; Goodnough LT
Hematology Am Soc Hematol Educ Program; 2010; 2010():153-9. PubMed ID: 21239786
[TBL] [Abstract][Full Text] [Related]
4. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
O'Connell KA; Wood JJ; Wise RP; Lozier JN; Braun MM
JAMA; 2006 Jan; 295(3):293-8. PubMed ID: 16418464
[TBL] [Abstract][Full Text] [Related]
5. Pediatric off-label use of recombinant factor VIIa.
Alten JA; Benner K; Green K; Toole B; Tofil NM; Winkler MK
Pediatrics; 2009 Mar; 123(3):1066-72. PubMed ID: 19255041
[TBL] [Abstract][Full Text] [Related]
6. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
Croom KF; McCormack PL
BioDrugs; 2008; 22(2):121-36. PubMed ID: 18345709
[TBL] [Abstract][Full Text] [Related]
7. Systemic venous thrombosis after recombinant factor VIIa in the control of bleeding after cardiac surgery.
Mahmoud A; Al-Ruzzeh S; McKeague H; Cross M
Tex Heart Inst J; 2007; 34(4):485-8. PubMed ID: 18172537
[TBL] [Abstract][Full Text] [Related]
8. A role for very low-dose recombinant activated factor VII in refractory bleeding after cardiac surgery: Lessons from an observational study.
Hoffmann T; Assmann A; Dierksen A; Roussel E; Ullrich S; Lichtenberg A; Albert A; Sixt S
J Thorac Cardiovasc Surg; 2018 Oct; 156(4):1564-1573.e8. PubMed ID: 29884487
[TBL] [Abstract][Full Text] [Related]
9. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
10. Con: The role of recombinant factor VIIa in the control of bleeding after cardiac surgery.
Al-Ruzzeh S; Ibrahim K; Navia JL
J Cardiothorac Vasc Anesth; 2008 Oct; 22(5):783-5. PubMed ID: 18922443
[No Abstract] [Full Text] [Related]
11. [Recombinant activated factor VII for perioperative bleeding].
López R; Aeschlimann N; Carvajal C; Lema G
Rev Med Chil; 2009 Jun; 137(6):837-43. PubMed ID: 19746288
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.
Chapman AJ; Blount AL; Davis AT; Hooker RL
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1314-8; discussion 1318-9. PubMed ID: 21601468
[TBL] [Abstract][Full Text] [Related]
13. Vascular injury and thrombotic potential: a note of caution about recombinant factor VIIa.
Mazer CD; Leong-Poi H; Mahoney J; Latter D; Strauss BH; Teitel JM
Semin Cardiothorac Vasc Anesth; 2007 Dec; 11(4):261-4. PubMed ID: 18270189
[TBL] [Abstract][Full Text] [Related]
14. Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.
Puetz J
Drug Des Devel Ther; 2010 Jul; 4():127-37. PubMed ID: 20689699
[TBL] [Abstract][Full Text] [Related]
15. Use of recombinant factor VIIa in hereditary bleeding disorders.
Poon MC
Curr Opin Hematol; 2001 Sep; 8(5):312-8. PubMed ID: 11604567
[TBL] [Abstract][Full Text] [Related]
16. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
17. Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7).
Hacquard M; Durand M; Lecompte T; Boini S; Briançon S; Carteaux JP
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1320-7. PubMed ID: 21550261
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
Simpson E; Lin Y; Stanworth S; Birchall J; Doree C; Hyde C
Cochrane Database Syst Rev; 2012 Mar; (3):CD005011. PubMed ID: 22419303
[TBL] [Abstract][Full Text] [Related]
19. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery.
Raivio P; Suojaranta-Ylinen R; Kuitunen AH
Ann Thorac Surg; 2005 Jul; 80(1):66-71. PubMed ID: 15975342
[TBL] [Abstract][Full Text] [Related]
20. Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage.
Rowe AS; Turner RM
Am J Health Syst Pharm; 2010 Mar; 67(5):361-5. PubMed ID: 20172985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
